Telisotuzumab Adizutecan  (Synonyms: ABBV-400; Temab-A)

Telisotuzumab Adizutecan (ABBV-400) is an anti-c-Met antibody-drug conjugate (ADC). Telisotuzumab Adizutecan is composed of the humanized anti-c-Met antibody Telisotuzumab (HY-P99391) and the topoisomerase 1 inhibitor (7-MAD-MDCPT) (HY-132162). Telisotuzumab Adizutecan exhibits significant anti-tumor activity against advanced solid tumors such as colorectal cancer, gastric cancer, and non-small cell lung cancer^[1][2][3].

Telisotuzumab Adizutecan can deliver cytotoxic payloads through c-Met targeting, and shows significant anti-tumor activity in colorectal cancer with high MET expression^[1][2][3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

149741 (average)

Liquid

Colorless to light yellow

[Telisotuzumab Adizutecan]

Shipping with dry ice.

-80°C, protect from light

• [1]. Sharma M, et al. First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer [J]. 2024.

  [2]. Sharma M, et al. Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors [J]. 2023.

  [3]. Park J, et al. MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies. Target Oncol. 2025 Sep;20(5):767-789.  [Content Brief]